Wandercraft Acquires Ekso Bionics to Expand Medical Exoskeleton Business

Wandercraft has acquired Ekso Bionics, with the seller being a subsidiary of ChronoScale Holdings. Both boards unanimously approved the transaction, signing and closing occurred simultaneously, and financial terms were not disclosed. This means outsiders cannot judge the size of the deal from the amount, valuation or payment method, nor assess its impact on either party's financial position.

The confirmable substance lies on the asset side: the combined portfolio includes Wandercraft's Atalante X and Eve, plus Ekso Bionics' EksoNR and Indego Personal — four products in total, spanning both rehabilitation training and personal mobility scenarios. Wandercraft says it will continue to support all four products along with their customers, clinicians and users.

It should be noted that the above information currently comes only from a single The AI Insider report, with no first-party announcement or cross-verification from other independent sources. So even though the transaction itself is a fact that has occurred, most business judgments surrounding it should still be treated as report relay rather than independently confirmed conclusions.

The first line is institutional rehabilitation. Atalante X and EksoNR are already used in more than 700 rehabilitation centers worldwide and hold U.S. FDA clearance and CE certification, covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury. This is the most direct existing asset after the merger: within the same cohort of rehabilitation centers, the two companies were previously competing or parallel options, and now they belong to one company.

The second line is personal use. Eve provides hands-free, self-balancing mobility, while Indego Personal is a modular wearable exoskeleton; both target eligible spinal cord injury populations. This line's product form differs from institutional equipment, and the sales target shifts from rehabilitation centers to individual users, making it more dependent on payers rather than procurement budgets.

The 700-plus rehabilitation centers is an aggregate figure given by the report, and it does not distinguish how many institutions each of Atalante X and EksoNR is used in; the statistical basis and cutoff date are also unclear. The specific indication scope of the FDA clearance and CE certification is likewise only summarized by the report, with no clearance numbers or documents listed. These figures can indicate order of magnitude, but are not suitable for extrapolating the installed base of any single product.

Wandercraft says the acquisition combines its Europe, Middle East and Africa business with Ekso Bionics' U.S. operations, clinical experience and commercial network. Ekso Bionics CEO Scott Davis said Ekso spent twenty years pioneering robotics technology, advancing engineering and R&D, and building a clinical research evidence base. Together these two statements form the deal logic: one side provides technology and EMEA channels, the other provides U.S. clinical accumulation and commercial reach.

This complementarity is currently the acquirer's claim, not an independently verified conclusion. Whether Ekso Bionics' U.S. clinical and commercial network can maintain its prior capabilities after the acquisition is a question the report does not answer; the report also does not explain the post-acquisition arrangements for Ekso Bionics' brand, management and employees.

On the service side, Wandercraft says the combined operation will provide rehabilitation centers with specialists familiar with both Atalante X and EksoNR, while maintaining product-specific support. This looks more like a preventive arrangement for channel conflict: handing overlapping customers to the same group of people, while not abandoning single-product specialist support.

Wandercraft already operates the Walk in New York rehabilitation center in the U.S., where patients have been training. The company also says it has a team in the U.S. helping users handle benefits, documentation, reimbursement, financing, and coordination with clinicians and insurers. These two items are its physical presence in the U.S., and a foundation it already had before acquiring Ekso Bionics' U.S. network.

Reimbursement is the key variable for personal exoskeleton commercialization. Wandercraft points out that Medicare bills under the brace benefit category using HCPCS code K1007, covering U.S. personal exoskeleton users who meet eligibility and medical necessity requirements. This statement comes from the acquirer, and the report does not cite official Medicare documents, so it can only be treated as a source claim.

The resulting uncertainty is specific: how Medicare coverage of personal exoskeletons is actually executed in real reimbursement and its applicable scope remain uncertain. For personal-facing products like Eve and Indego Personal, there is still a distance between the existence of a code and smooth reimbursement, and that distance is precisely what determines whether the personal mobility line can scale.

Wandercraft only says it will continue to support existing products, without stating whether the post-merger product line will be consolidated or discontinued. The four products overlap functionally in rehabilitation scenarios and occupy different form factors in personal scenarios; whether they will operate in parallel long-term is a direction the report does not provide.

What can be confirmed is the transaction structure itself: unanimous board approval and simultaneous signing and closing indicate this is a completed transaction, not a letter of intent or framework agreement. But the transaction amount and valuation are unknown, making it impossible to judge the impact on either party's finances, or to infer from price which product line the acquirer values more.

The news comes from a single source only, and whether first-party confirmation or independent reporting from other media will follow remains uncertain. Until more information emerges, assessment of this deal should stay at the level of product portfolio and geographic coverage, rather than extending to market share or financial impact.